Neurelis Announces 12 Poster Presentations for the Annual Meeting of the American Epilepsy Society
— Abstracts continue to demonstrate the safety and unique clinical attributes of Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for episodes of frequent seizure activity in pediatric patients 6 years of age and older, adolescents, and adults — Data also highlight the ability for patients to self-administer VALTOCO […]